Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.73 |
| ▸ | JAK1 | P23458 | 19/20 | 0.73 |
| ▸ | TYK2 | P29597 | 6/20 | 0.73 |
| ▸ | JAK3 | P52333 | 6/20 | 0.73 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613863 | 1.00 | JAK2 (0.73) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19259510 | 0.88 | JAK2 (0.76) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19275206 | 0.88 | JAK2 (0.60) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19275278 | 0.88 | JAK2 (0.58) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19259672 | 0.87 | JAK2 (0.65) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL30613885 | 0.87 | JAK2 (0.65) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19259578 | 0.86 | JAK2 (0.70) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL19259642 | 0.86 | JAK2 (0.61) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL23495084 | 0.85 | JAK2 (0.55) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL30377809 | 0.85 | JAK2 (0.55) | JAK2JAK1TYK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| EP-3416967-B1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2022-02-09 | — | — | EP | disclosed |
| CN-108473501-B | Therapeutic compounds, compositions and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| EP-3416967-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017140825-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 20/4885 |
| US-11795170-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 37/4885 |
| US-20180354959-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 40/4885 |
| US-11649241-B2 | Pyrazolochlorophenyl compounds, compositions and methods of use thereof | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 20/4885 |
| US-20210009599-A1 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885TYK2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.